Evidence map›Paper›PMID 34502328›Full record

ArticleInternational journal of molecular sciences2021

Formulation, Characterization and Cytotoxicity Effects of Novel Thymoquinone-PLGA-PF68 Nanoparticles.

Nurul Shahfiza Noor, Noor Haida Mohd Kaus, Myron R Szewczuk, Shahrul Bariyah Sahul Hamid

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. α-Acylamino-β-lactoneAntioxidants (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nurul Shahfiza NoorOncological and Radiological Sciences Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, Kepala Batas 13200, Penang, Malaysia.
Noor Haida Mohd KausDepartment of Physical Chemistry, School of Chemical Sciences, Universiti Sains Malaysia, Gulong 11800, Penang, Malaysia.ORCID 0000-0002-6257-7302
Myron R SzewczukDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.ORCID 0000-0001-8471-5481
Shahrul Bariyah Sahul HamidOncological and Radiological Sciences Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, Kepala Batas 13200, Penang, Malaysia.

Funding

Fundamental Reasearch Grant Scheme 203/CIPPT/6711540Research University Grant 1001/CIPPT/812138
6 · The paper itself

Abstract

Thymoquinone has anti-cancer properties. However, its application for clinical use is limited due to its volatile characteristics. The current study aims to develop a polymeric nanoformulation with PLGA-PEG and Pluronics F68 as encapsulants to conserve thymoquinone's (TQ) biological activity before reaching the target sites. Synthesis of nanoparticles was successfully completed by encapsulating TQ with polymeric poly (D, L-lactide-co-glycolide)-block-poly (ethylene glycol) and Pluronics F68 (TQ-PLGA-PF68) using an emulsion-solvent evaporation technique. The size and encapsulation efficiency of TQ-PLGA-PF68 nanoparticles were 76.92 ± 27.38 nm and 94%, respectively. TQ released from these encapsulants showed a biphasic released pattern. Cytotoxicity activity showed that tamoxifen-resistant (TamR) MCF-7 breast cancer cells required a higher concentration of TQ-PLGA-PF68 nanoparticles than the parental MCF-7 cells to achieve IC

Indexed as

Drug Resistance, NeoplasmAntineoplastic Agents, PhytogenicBenzoquinonesBreast NeoplasmsDrug CompoundingFemaleHumansMCF-7 CellsNanoparticlesPaclitaxelPoloxamerPolylactic Acid-Polyglycolic Acid CopolymerAntineoplastic Agents, PhytogenicBenzoquinonesPaclitaxelPoloxamerPolylactic Acid-Polyglycolic Acid Copolymerthymoquinoneemulsion–solvent evaporationPLGA-PEGPluronics F68resistant breast cancerTQ-PLGA-PF68

Identifiers

PMID34502328
PMCPMC8431343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.